Amneal Pharmaceuticals, Inc. Class A Common Stock AMRX
$19.45
-2.51%
at last close
Analyst Consensus
- Consensus Rating
- Buy (6 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $23.17
- Implied Upside
- +19.1%
- Price Target Range
- $17.00 – $27.00
- Analysts (12 mo)
- 6
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-11-05 | Leerink PartnersDaniel Clark |
Maintains | Outperform | $23 → $25 |
| 2026-11-04 | JP MorganChris Schott |
Maintains | Overweight | $24 → $25 |
| 2026-10-22 | JP MorganChris Schott |
Maintains | Overweight | $22 → $24 |
| 2026-09-23 | OppenheimerLes Sulewski |
Initiates coverage on | Outperform | $27 |
| 2026-09-17 | BarclaysGlen Santangelo |
Maintains | Overweight | $16 → $20 |
| 2026-09-09 | Leerink PartnersDaniel Clark |
Initiates coverage on | Outperform | $23 |
| 2026-08-26 | JP MorganChris Schott |
Reinstates | Overweight | $22 |
| 2026-08-03 | UBSAshwani Verma |
Maintains | Buy | $23 → $25 |
| 2026-07-15 | UBSAshwani Verma |
Maintains | Buy | $19 → $23 |
| 2026-05-20 | BarclaysGlen Santangelo |
Maintains | Overweight | $15 → $16 |
| 2026-04-17 | UBSAshwani Verma |
Initiates coverage on | Buy | $19 |
| 2026-03-02 | Truist SecuritiesLes Sulewski |
Maintains | Buy | $15 → $17 |
| 2025-12-09 | BarclaysGlen Santangelo |
Initiates coverage on | Overweight | $15 |
| 2025-10-31 | Piper SandlerDavid Amsellem |
Reiterates | Overweight | $11 → $13 |
| 2025-09-16 | JP MorganChris Schott |
Maintains | Overweight | $12 → $14 |
| 2025-03-03 | BarclaysBalaji Prasad |
Maintains | Overweight | $10 → $11 |
| 2025-02-24 | JP MorganChris Schott |
Upgrades | Neutral → Overweight | $9 → $12 |
| 2024-11-11 | Piper SandlerDavid Amsellem |
Maintains | Overweight | $9 → $11 |
| 2024-10-02 | Truist SecuritiesLes Sulewski |
Maintains | Buy | $10 → $12 |
| 2024-09-06 | JP MorganChris Schott |
Upgrades | Underweight → Neutral | $9 |
| 2024-08-13 | BarclaysBalaji Prasad |
Maintains | Overweight | $8 → $10 |
| 2024-08-12 | Truist SecuritiesLes Sulewski |
Maintains | Buy | $9 → $10 |
| 2024-05-06 | Goldman SachsNathan Rich |
Maintains | Buy | $6 → $8 |
| 2024-05-06 | Truist SecuritiesLes Sulewski |
Reiterates | Buy | $7 → $9 |
| 2024-03-21 | Piper SandlerDavid Amsellem |
Maintains | Overweight | $6 → $8 |
| 2024-03-04 | Goldman SachsNathan Rich |
Maintains | Buy | $6 → $6 |
| 2024-01-29 | BarclaysBalaji Prasad |
Maintains | Overweight | $6 → $8 |
| 2023-11-08 | Truist SecuritiesGregory Fraser |
Maintains | Buy | $6 → $7 |
| 2023-09-06 | Truist SecuritiesGregory Fraser |
Reiterates | Buy | $6 |
| 2023-08-07 | Piper SandlerDavid Amsellem |
Maintains | Overweight | $3 → $5 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $19.45
- Market Cap
- $6.95 billion
- 52-Week Range
- $9.56 – $21.68
- Average Volume
- 4.13 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.